Home›Trial›NCT06312189
NCT06312189Phase 3ENROLLING BY INVITATION

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Study Summary

This study will evaluate long-term safety and tolerability of valbenazine in participants with chorea associated with Huntington Disease (HD) who participated in Study NBI-98854-HD3006 (NCT04400331) in Canada.

Conditions
Chorea, Huntington
Interventions / Drugs
Valbenazine
View on ClinicalTrials.gov ↗
Sponsor
NBIX
Neurocrine Biosciences
Neuroscience
C58/100
Study Details
Enrollment7 participants
Primary Completion—
Lead SponsorNeurocrine Biosciences
Data Retrieved2026-04-11 04:22:17.614644+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 3 trials are pivotal studies with large patient populations (hundreds to thousands) designed to prove efficacy and safety for FDA submission. A successful Phase 3 readout is typically the last major hurdle before a New Drug Application (NDA) or BLA filing.

Status & Expected Data

Current status: ENROLLING BY INVITATION.

Enrolled: 7 participants
Sponsor Catalyst Profile

Neurocrine Biosciences (NBIX) is the sponsoring company for this trial. BiotechSign currently grades this company C (58/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

NBIX Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.